Related Experiment Videos
Functional oxytocin receptors discovered in human osteoblasts
J A Copland1, K L Ives, D J Simmons
1University of Texas Medical Branch, Dept of Obstetrics and Gynecology, Galveston 77555, USA.
Endocrinology
|August 28, 1999
Summary
Oxytocin receptors (OTRs) are present in human bone cells and osteosarcoma cells. Oxytocin stimulates prostaglandin E2 synthesis, suggesting oxytocin may promote bone formation.
Area of Science:
- Endocrinology
- Bone Biology
- Cell Signaling
Background:
- Oxytocin is a hormone primarily known for its roles in reproduction and social bonding.
- The presence and function of oxytocin receptors (OTRs) in bone cells have not been previously investigated.
- Understanding hormonal influences on bone metabolism is crucial for developing treatments for bone diseases.
Purpose of the Study:
- To investigate the expression of oxytocin receptors (OTRs) in human osteoblastic cells.
- To determine the functional consequences of oxytocin (OT) stimulation on these cells.
- To explore the potential role of oxytocin as a bone anabolic agent.
Main Methods:
- Analysis of OTR mRNA and protein expression in primary human trabecular bone cells and Saos-2 osteosarcoma cells.
- Measurement of intracellular calcium concentration ([Ca2+]i) changes in response to oxytocin.
- Assessment of prostaglandin E2 (PGE2) synthesis following oxytocin stimulation.
Main Results:
- Oxytocin receptors (OTRs) were detected at both mRNA and protein levels in undifferentiated and differentiated human trabecular bone cells, as well as in Saos-2 cells.
- Oxytocin stimulation led to a significant increase in intracellular calcium, which was blocked by an oxytocin antagonist, confirming functional OTRs.
- Oxytocin treatment stimulated prostaglandin E2 (PGE2) synthesis in osteoblastic cells.
Conclusions:
- Human osteoblastic cells express functional oxytocin receptors (OTRs).
- Oxytocin signaling in bone cells involves increased intracellular calcium and prostaglandin E2 (PGE2) production.
- Oxytocin may represent a novel therapeutic agent for promoting bone formation and treating bone loss.